Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients
Key facts
- Who runs it
- Bangladesh Medical University
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 50 people enrolled
- Started
- 1 Mar 2024
- Ended
- 28 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Leflunomide plus Methotrexate
- Methotrexate Monotherapy
- Record updated
- 23 February 2026
Who can take part
- Age
- 1 day to 15 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- All diagnosed cases of Refractory Polyarticular Juvenile Idiopathic Arthritis (JIA) according to ILAR, 2001 unresponsive to methotrexate (at standard dose of 15mg/m² body surface area at least 3-6 months) as monotherapy or together with low dose steroid as bridge therapy who attended Paediatric Rheumatology Division (OPD clinic and inpatient), Department of Paediatrics of BMU, during the study period
Who cannot take part
- 1. A patient with prior or current infectious disorders, including active/latent tuberculosis, and/or H/O chronic or recurrent severe infections, including opportunistic infections; A patient with leucopenia (White blood cell count < 3000/mm3), neutropenia (Neutrophil count < 1000/mm3) and thrombocytopenia (Platelet count < 100000/mm3); Serum creatinine > upper limit of normal reference range. 4. Alanine aminotransaminase (ALT) more than 2 times of upper normal limit. 5. All diagnosed cases of refractory polyarticular JIA who did not give the consent during the study period
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized control trial open level and parallel design was conducted in the department of paediatrics, Bangladesh Medical University (BMU). All diagnosed cases of Refractory Polyarticular JIA according to ILAR criteria, unresponsive to MTX were enrolled in this study. After getting written informed consent from the parents/legal guardians, a detailed structured data collection sheet was used for data collection. After enrollment all participants were allocated into experimental group and control group by randomization using random allocation software version 2.0. Total sample size of this study is 50 and 25 participants in each group. All patients of experimental group were given leflunomide along with existing MTX in refractory polyarticular JIA patients and injectable MTX were given at standard dose(15mg/m² BSA) Considering high disease activity steroid were continued in both group at low bridging dose 0.05-1 mg/kg/dose. Patient's disease activity status was assessed by JADAS-27 at initial visit, 6th weeks, 12 weeks and 24 weeks. Functional impairment was assessed by CHAQ-B (DI) at baseline and 24th weeks of treatment. Statistical analysis of the collected data were carried out by using an appropriate statistical tool.
The 2 groups in the trial
- Leflunomide plus Methotrexate (Experimental group)Treatment being tested
Experimental group
Treatment: Leflunomide plus Methotrexate
- Methotrexate Monotherapy (Control Group)Existing treatment, for comparison
Control group
Treatment: Methotrexate Monotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 February 2026